Bavarian Nordic stock

BAVA · Nasdaq Copenhagen · DKK

kr 237.60Change from previous close: +0.17%Absolute change: +kr 0.40

Close · November 16, 2026

Price history

+29.10% over the period

1 year: from kr 184.05 (November 17, 2025) to kr 237.60 (November 16, 2026), +29.10%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026kr 237.60
October 30, 2026kr 245.40
September 30, 2026kr 221.00
August 31, 2026kr 217.60
July 31, 2026kr 177.90
June 30, 2026kr 182.70
May 29, 2026kr 187.40
April 30, 2026kr 187.20
March 31, 2026kr 193.05
February 27, 2026kr 197.50
January 30, 2026kr 192.00
December 30, 2025kr 190.85
November 28, 2025kr 184.75
November 17, 2025kr 184.05

At a glance

  • The company

    Develop, manufacture and supply life-saving vaccines for smallpox, monkeypox, rabies, tick-borne encephalitis, cholera and typhoid fever

  • Latest results

    Quarter to June 30, 2026 · EPS kr 9.40 (estimate kr 4.50)

TickerLandia's take on Bavarian Nordic

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowkr 171.30
52-wk highkr 257.00

−7.55% from the 52-week high

Analysts · 4 analysts

Average targetkr 291.25+22.58% vs. price

Buy 4 · Hold 0 · Sell 0 · Strong buy

TickerLandia Fingerprint: Bavarian Nordic

Compared with similar companies: very low price and very high financial strength.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Bavarian Nordic is cheaper than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Bavarian Nordic's P/E today is 13.5, below the median of its last 6 fiscal years (23.1; between 9.24 and 197.0 from 2016 to 2025). Bavarian Nordic's P/E (trailing 12 months): 12.2, −29% against the median of a group of 9 similar companies (17.1).

P/E compared with its history

Compared with 9 similar companies

Bavarian Nordic's metrics compared with similar companies
MetricBavarian NordicPosition in the groupBand
P/E (trailing 12 months)12.2Middle
Forward P/E19.8Middle
Operating margin18.1%Low
ROE12.2%Middle
Debt/equity0.01Low

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Bavarian Nordic. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

kr 2.03B

Latest quarter · Q2 2026

Net income

kr 731.64M

Latest quarter · Q2 2026

Quarterly net margin

36.0%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
kr 17.7B
P/E
12.2
EPS
kr 19.50
Volume
298.21K
Daily trading
€6.18M
Dividend yield
0.00%

How Bavarian Nordic is changing

All results
  • Revenue grew 27.5% a year on average over the last 5 years

  • Operating margin rose from −2.2% to 16.6%

  • Profits turn into cash: free cash flow equal to 140% of net income

Returns

Bavarian Nordic returns

kr 1,000 invested in Bavarian Nordic 5 years ago, on November 16, 2021, would be worth kr 759 today: −24.11% in total, −5.37% per year. This is the price return only: dividends are excluded.

PeriodBavarian Nordickr 1,000 becomes
1 month+0.25%kr 1,003
6 months+26.18%kr 1,262
Year to date+24.50%kr 1,245
1 year+29.10%kr 1,291
3 years+66.85%kr 1,669
5 years−24.11%kr 759
10 years+27.27%kr 1,273

Price only, without dividends. Calculate your investment

The chart in detail

Bavarian Nordic: technical analysis

Bavarian Nordic is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 40.9% below its all-time closing high (kr 401.70, August 3, 2022).

Trend
Upward
RSI (14 sessions)
48
Between 30 and 70
vs 200-session average
+19.00%

Support and resistance

Price areas where Bavarian Nordic has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last pricekr 237.60
  3. Supportkr 223.40−5.98%2 touches, last on September 23, 2026
  4. Supportkr 202.90−14.60%3 touches, last on May 12, 2026
  5. Supportkr 198.98−16.25%5 touches, last on September 15, 2026

Volatility and risk

Volatility (60 sessions, annualised)
26.6%
Largest fall in the last year
−14.18%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Bavarian Nordic: seasonality

Average monthly price change over 27 years

+4.7%Jan+0.0%Feb+0.5%Mar+6.5%Apr+5.7%May−3.2%Jun+4.7%Jul+0.1%Aug−6.0%Sep+3.6%Oct+0.7%Nov+0.6%Dec

Over the last 27 years, the strongest month for Bavarian Nordic has been April: +6.50% on average, positive in 17 years out of 27. The weakest has been September: −5.98% on average, positive in 12 years out of 27. November, the current month, has been positive in 11 years out of 26 (+0.65% on average).

Show chart data
MonthAverageMedianPositive years
January+4.71%+2.99%17 of 26
February+0.02%+0.55%15 of 27
March+0.52%−2.25%10 of 27
April+6.50%+3.11%17 of 27
May+5.75%+3.02%17 of 27
June−3.23%−3.88%6 of 27
July+4.71%+3.35%18 of 27
August+0.09%−2.73%11 of 27
September−5.98%−3.47%12 of 27
October+3.58%+0.40%14 of 27
November+0.65%−1.17%11 of 26
December+0.64%+1.18%14 of 26

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Bavarian Nordic and its competitors

Employing 1,906 people, the company develops and supplies vaccines against infectious diseases, with its portfolio centred on smallpox and monkeypox vaccines sold as JYNNEOS, IMVANEX and IMVAMUNE. Other products include a rabies vaccine marketed as Rabipur and RabAvert, the tick-borne encephalitis vaccine Encepur, and two oral vaccines, Vaxchora against cholera and Vivotif/Typhoral against typhoid fever. Sales and operations span the United States, Canada, several European countries, Japan, Singapore, Taiwan, Saudi Arabia and Australia, and the company is also developing MVA-BN WEV, a candidate under study for encephalitis viruses.

Headquarters
Hellerup, Denmark
Employees
1,906
Founded
1992
Chief executive
Paul Chaplin
Bavarian Nordic and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Bavarian NordicBAVA$2.62B18.1%12.2+26.18%
BioArcticBIOA.B$2.74B19.6%262.7−3.82%
Zealand PharmaZEAL$2.37B59.0%5.49−20.61%
Lakefront BiotherapeuticsLKFT$2.2B57.5%3.21+33.42%
CamurusCAMX$4.41B37.4%58.9+46.61%
Pharma MarPHM$1.28B21.3%17.1−29.91%

Same industry or related industries, similar size. Compare Bavarian Nordic with its competitors · Full profile